🟢 Outlook Therapeutics is trading 5.62% up today in after-hours trading after third-quarter earnings and launch updates

Outlook Therapeutics is trading at $0.80, +5.62% in after-hours trading following third-quarter results and LYTENAVA launch updates.

• Reported third-quarter adjusted net loss of $10.9 million, or $0.09 per share, while preparing LYTENAVA’s U.S. launch.
• Management reaffirmed a late-2026 launch and highlighted approximately $51.1 million in net proceeds from an August equity-and-warrant offering, improving funding but creating dilution.
• The rebound follows a 14.90% regular-session decline; no separate late-breaking announcement was identified.